A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

@article{Khuri2000ACT,
  title={A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer},
  author={Fadlo R. Khuri and John Nemunaitis and Ian Ganly and James C. Arseneau and Ian F. Tannock and Larry Romel and Martin Gore and Janet A D Ironside and Robert Macdougall and Carla Heise and Britta Randlev and Ann Gillenwater and P. Bruso and Stanley B. Kaye and Waun Ki Hong and David H. Kirn},
  journal={Nature Medicine},
  year={2000},
  volume={6},
  pages={879-885}
}
ONYX-015 is an adenovirus with the E1B 55-kDa gene deleted, engineered to selectively replicate in and lyse p53-deficient cancer cells while sparing normal cells. Although ONYX-015 and chemotherapy have demonstrated anti-tumoral activity in patients with recurrent head and neck cancer, disease recurs rapidly with either therapy alone. We undertook a phase II trial of a combination of intratumoral ONYX-015 injection with cisplatin and 5-fluorouracil in patients with recurrent squamous cell… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 395 CITATIONS, ESTIMATED 50% COVERAGE

Immune System, Friend or Foe of Oncolytic Virotherapy?

  • Front. Oncol.
  • 2017
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Replication-selective viruses for cancer therapy

VIEW 8 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Adenoviral vector-based strategies against infectious disease and cancer

  • Human vaccines & immunotherapeutics
  • 2016
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Oncolytic Viruses in the Treatment of Cancer: A Review of Current Strategies

  • Pathology & Oncology Research
  • 2012
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

The feasibility of gene therapy in the treatment of head and neck cancer

  • Head & neck oncology
  • 2009
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

1994
2019

CITATION STATISTICS

  • 14 Highly Influenced Citations

  • Averaged 8 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 45 REFERENCES

A phase I study of Onyx-015, an EIB attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer

I Ganly
  • Clin. Cancer Res
  • 2000

Evidence for a causal association between human papillomavirus and a subset of head and neck cancers

Gillison, M.L
  • J. Natl. Cancer Inst
  • 2000

intratumoral spread and distribution effects

O. Wildner, R. M. Blaese, +6 authors D. Efficacy of a replication-competent adenovirus fol injection
  • Cancer Gene Ther. 6, 499–504
  • 1999

A phase II trial of intratumoral injection with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer

D Kirn
  • Proc. Am. Soc. Clin. Oncol. 17,
  • 1998

Similar Papers

Loading similar papers…